# Keros Therapeutics, Inc. (KROS) · Edgar & Edgarette company card

> Keros Therapeutics (KROS) grew revenue 6775% in FY2025 to $244 million, operating margin 27.7% against a -3.8% median for pharmaceutical preparations, equity 89.7% of assets. Every figure is from the company’s own annual report filed with the SEC.

SEC CIK 1664710 · fiscal year ended 2025-12-31 · 5 audited years read · [page](https://www.pops4.com/boards/company/KROS) · [JSON](https://www.pops4.com/boards/company/KROS.json)

## Figures, as filed in the 10-K

| Measure | Value |
|---|---|
| Revenue | $244M |
| Revenue growth, 1 year | 6775.0% |
| Revenue growth per year | 86.7% |
| Operating margin | 27.7% (prior year -5939.0%) |
| Net margin | 35.7% |
| Operating cash flow | $108M |
| Capital spending | $2M |
| Free cash flow | $106M |
| Cash | $287M |
| Long-term debt | — |
| Total assets | $338M |
| Total equity | $303M |
| Equity ÷ assets | 89.7% |
| Return on equity | 28.7% |
| Dividend per share | — |
| Dividend years rising | — |

## Readings, computed from those figures

- Altman Z: 11.55 (safe zone)
- Piotroski F: 6 of 9 (solid)
- Health Harbor boat: New ship · no warning signs

## Edgarette's reading

Exposure: revenue $244.1M (FY2025). Experience: revenue up 6775.0% on the year, up 86.7% a year over 4 years; operating margin 27.7%, up from -5939.0%. Soundness: equity 89.7% of assets, return on equity 28.7%. Credibility: four or more audited years, reasonable weight. Range: 80% of past cases like this landed between $6.8B and $10.9B next year (method v3, set from 4,309 SEC company-years; on a year the method never saw, 83% landed inside). A statistical range, not company guidance. Against peers (114 filers, $50M+ revenue, pharmaceutical preparations): operating margin 27.7% against a -3.8% median; growth 6775.0% against 13.7%.

Range logged 2026-09-20, receipt 265b50475e57ddb6, status open. A statistical range, not company guidance.

## Health Watch, last 12 months

- Item 5.02 Director or officer change: 3, latest 2026-07-22 ([filing](https://www.sec.gov/Archives/edgar/data/1664710/000166471026000038/0001664710-26-000038-index.htm))

## Recent filings

- 8-K · filed 2026-09-29 · 7.01 Regulation FD Disclosure; 9.01 Financial Statements and Exhibits · [filing](https://www.sec.gov/Archives/edgar/data/1664710/000166471026000059/0001664710-26-000059-index.htm)
- 8-K · filed 2026-09-28 · 7.01 Regulation FD Disclosure; 9.01 Financial Statements and Exhibits · [filing](https://www.sec.gov/Archives/edgar/data/1664710/000166471026000056/0001664710-26-000056-index.htm)
- 8-K · filed 2026-09-08 · 8.01 Other Events; 9.01 Financial Statements and Exhibits · [filing](https://www.sec.gov/Archives/edgar/data/1664710/000166471026000053/0001664710-26-000053-index.htm)
- 8-K · filed 2026-08-03 · 7.01 Regulation FD Disclosure; 9.01 Financial Statements and Exhibits · [filing](https://www.sec.gov/Archives/edgar/data/1664710/000166471026000050/0001664710-26-000050-index.htm)
- 10-Q · filed 2026-08-03 · [filing](https://www.sec.gov/Archives/edgar/data/1664710/000166471026000049/0001664710-26-000049-index.htm)
- 8-K · filed 2026-08-03 · 2.02 Results of Operations and Financial Condition; 9.01 Financial Statements and Exhibits · [filing](https://www.sec.gov/Archives/edgar/data/1664710/000166471026000048/0001664710-26-000048-index.htm)

## Sources

- facts: https://data.sec.gov/api/xbrl/companyfacts/CIK0001664710.json
- filings: https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=1664710

## Cite

POPS4, Edgar & Edgarette: Keros Therapeutics, Inc. (KROS) company card, from the company's own SEC filings, accessed 2026-11-04, https://www.pops4.com/boards/company/KROS. CC BY 4.0. For a figure, add the filing URL under filings or sources.

DOI https://doi.org/10.5281/zenodo.23672509 · catalog https://www.pops4.com/boards/catalog.json · Figures as filed with the SEC. Card text CC BY 4.0, POPS4.

Reporting, not investment advice. No price targets and no trading recommendations.

Figures are as filed in audited 10-K reports and can move with restatements, acquisitions, disposals or a change in fiscal year. A range set from how past company-years turned out is not a promise about the next one, and says nothing about the share price.